Update on primary sclerosing cholangitis

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 66, Issue 2, Pages (February 2017)
Volume 63, Issue 1, Pages (July 2015)
The impact of hepatitis E in the liver transplant setting
Immunosuppression After Liver Transplantation for Primary Sclerosing Cholangitis Influences Activity of Inflammatory Bowel Disease  Kristin Kaasen Jørgensen,
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Inflammasomes in liver diseases
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Autoimmune liver disease, autoimmunity and liver transplantation
Pathological roles of purinergic signaling in the liver
Novel insights in the interplay between inflammation and metabolic diseases: A role for the pathogen sensing kinase PKR  Nicolas Marsollier, Pascal Ferré,
The potential beneficial role of faecal microbiota transplantation in diseases other than Clostridium difficile infection  R. Singh, M. Nieuwdorp, I.J.M.
Anatoliy I. Masyuk, Tatyana V. Masyuk, Nicholas F. LaRusso 
The impact of hepatitis E in the liver transplant setting
Reactive oxygen species in the normal and acutely injured liver
Cédric Coulouarn, Bruno Clément  Journal of Hepatology 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
The gut microbiota and the liver
Metagenomics and Personalized Medicine
Living donor liver transplantation: is the hype over?
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Gut–liver immunity Journal of Hepatology
European Association for the Study of the Liver  Journal of Hepatology 
Effects of Coffee Consumption, Smoking, and Hormones on Risk for Primary Sclerosing Cholangitis  Ina Marie Andersen, Guro Tengesdal, Benedicte Alexandra.
Mesenchymal stromal cell therapy for liver diseases
Biology of the immunomodulatory molecule HLA-G in human liver diseases
Genetics of liver disease: From pathophysiology to clinical practice
European Association for the Study of the Liver  Journal of Hepatology 
Hepatitis C core protein – The “core” of immune deception?
IgG4 cholangiopathy – Current concept, diagnosis, and pathogenesis
Acute-on chronic liver failure
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
A dive into the complexity of type I interferon antiviral functions
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Autophagy and senescence in fibrosing cholangiopathies
Volume 62, Issue 3, Pages (March 2015)
Figure 4 The gut–liver relationship in PSC
Genomic risk of hepatitis C-related hepatocellular carcinoma
Unmet clinical need in autoimmune liver diseases
Volume 59, Issue 3, Pages (September 2013)
Liver transplantation for primary sclerosing cholangitis
EASL Clinical Practice Guidelines: Wilson’s disease
EASL Recognition Award Recipient 2017: Prof. Giorgina Mieli-Vergani
Inflammatory Bowel Disease Is Associated With Poor Outcomes of Patients With Primary Sclerosing Cholangitis  Jing Hieng Ngu, Richard Blair Gearry, Andrew.
Giovanni Addolorato, Antonio Mirijello, Pablo Barrio, Antoni Gual 
The changing role of beta-blocker therapy in patients with cirrhosis
Osteoarthritis year 2012 in review: genetics and genomics
Volume 63, Issue 2, Pages (August 2015)
Autoimmune pancreatitis/IgG4-associated cholangitis and primary sclerosing cholangitis – Overlapping or separate diseases?  George J.M. Webster, Stephen.
Cédric Coulouarn, Bruno Clément  Journal of Hepatology 
Paul C. Adams, James C. Barton  Journal of Hepatology 
Immunosuppression After Liver Transplantation for Primary Sclerosing Cholangitis Influences Activity of Inflammatory Bowel Disease  Kristin Kaasen Jørgensen,
Primary Sclerosing Cholangitis and Disease Distribution in Inflammatory Bowel Disease  Aoibhlinn O'Toole, Alaa Alakkari, Denise Keegan, Glen Doherty, Hugh.
miR-122 – A key factor and therapeutic target in liver disease
Benjamin A. Rybicki, Robert C. Elston 
Clinical Practice Guidelines of the European Association for the study of the Liver – Advancing methodology but preserving practicability  Markus Cornberg,
Global burden of alcoholic liver diseases
HCV targeting of patients with cirrhosis
Volume 44, Issue 5, Pages (May 2006)
Volume 63, Issue 1, Pages (July 2015)
Volume 151, Issue 4, Pages (October 2016)
The dynamic biliary epithelia: Molecules, pathways, and disease
Osteoarthritis year 2012 in review: genetics and genomics
Volume 54, Issue 2, Pages (February 2011)
Pathogenesis of cholestatic hepatitis C
Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing  Roongruedee Chaiteerakij,
Metagenomics and Personalized Medicine
Genetics of hepatocellular carcinoma: The next generation
Volume 75, Issue 7, Pages (April 2009)
Presentation transcript:

Update on primary sclerosing cholangitis Tom H. Karlsen, Kirsten Muri Boberg  Journal of Hepatology  Volume 59, Issue 3, Pages 571-582 (September 2013) DOI: 10.1016/j.jhep.2013.03.015 Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Published articles reporting the search term “primary sclerosing cholangitis” (http://www.ncbi.nlm.nih.gov/pubmed/). The present review will focus on articles published from 2010 to 2012. Journal of Hepatology 2013 59, 571-582DOI: (10.1016/j.jhep.2013.03.015) Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Venn diagram illustrating the genetic overlap between primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD). A total of 163 IBD susceptibility loci and 16 PSC susceptibility loci were included in the plot [9,158]. The major histocompatibility complex (MHC) associations in PSC include several independent association signals and are counted as one PSC specific locus. Journal of Hepatology 2013 59, 571-582DOI: (10.1016/j.jhep.2013.03.015) Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Relationship between pathogenesis of primary sclerosing cholangitis (PSC) and ongoing studies aimed at elucidating disease mechanisms and potential therapeutic targets. Importantly, the core processes of PSC development remain obscure. However, efforts now delineating mechanisms for bile duct injury and hepatobiliary inflammation in general, as well as in secondary sclerosing cholangitis (SSC), are likely to be useful in the definition of novel treatment strategies even though they may only partly relate to PSC pathogenesis. The only approach fully relevant to human PSC is the human genetic association studies, but they only account for a fraction of the liability in PSC [9], underscoring the role of environmental factors, including the gut microbiota and factors interacting with the gut microbiota [51]. IBD; inflammatory bowel disease. Journal of Hepatology 2013 59, 571-582DOI: (10.1016/j.jhep.2013.03.015) Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Fig. 4 Concept of the relationship between environmental and genetic risk factors for sclerosing cholangitis. Secondary sclerosing cholangitis (SSC) entities cluster at both ends of this spectrum (e.g., genetic causes versus infectious causes, respectively), whereas primary sclerosing cholangitis (PSC) is a complex phenotype involving multiple, interacting genetic and environmental factors. Factors involved in the development of SSC may modify or complicate disease course in PSC (e.g., ABCB4 variants and cholangitis, respectively). Journal of Hepatology 2013 59, 571-582DOI: (10.1016/j.jhep.2013.03.015) Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2013 59, 571-582DOI: (10. 1016/j. jhep. 2013. 03 Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2013 59, 571-582DOI: (10. 1016/j. jhep. 2013. 03 Copyright © 2013 European Association for the Study of the Liver Terms and Conditions